bivalirudin

Original Contribution

Evaluation of Bivalirudin-Associated Major Adverse Cardiac and Hemorrhagic Events in Acute Coronary Syndrome Patients on Chronic Dialysis Following Percutaneous Coronary Intervention

11/01/2021

Dongliang Fu, MD¹; Mengru Liu, MD²; Tong Gao, MD²; Chunyan Li, MD¹; Jiangquan Liao, MD¹; Mingjing Shao, MM¹; Xiang Xiao, MD¹; Peng Yang, MMed¹; Xianlun Li, MD¹; Hong Jiang, MD¹

Dongliang Fu, MD1; Mengru Liu, MD2; T...

Dr. Fu and colleagues evaluated MACE and hemorrhagic event rates for an antithrombotic regimen using bivalirudin or UFH during PCI in ACS patients.

Dr. Fu and colleagues evaluated...

11/01/2021

Journal of Invasive Cardiology

Original Contribution

Heparin Versus Bivalirudin in ST-Segment Elevation Myocardial Infarction: A SCAI-Based National Survey From US Interventional Cardiologists

09/01/2016

Harsh Golwala, MD¹; Sadip Pant, MD¹; Ambarish Pandey, MD²; Michael P. Flaherty, MD, PhD¹; Glenn A. Hirsch, MD, MHS¹; Ajay J. Kirtane, MD, SM³

Harsh Golwala, MD1; Sadip Pant, MD1;...

This survey was conducted to better understand current United States (US) practices in terms of preferences regarding the selection of antithrombotic therapy in STEMI-PPCI, particularly in light of recent clinical trials.

This survey was conducted to...

09/01/2016

Journal of Invasive Cardiology

Original Research

Bivalirudin in Peripheral Vascular Interventions: A Single Center Experience

09/05/2008

Nicolas W Shammas; Jon H Lemke; Eric J. Dippel; Dawn E. McKinney; Vickie S, Takes; Monica Youngblut; Melodee Harris

Nicolas W Shammas; Jon H Lemke; Eric ...

Unfractionated heparin is the current antithrombotic agent utilized during peripheral angioplasty procedures.

Unfractionated heparin is the...

09/05/2008

Vascular Disease Management

Update

Update: Bivalirudin in Peripheral Vascular Intervention

09/05/2008

Nicolas W Shammas, MD

Despite the sharp rise in peripheral vascular interventions (PVI), complication rates have continued to be significant and, in fact, limb loss has trended upwards.

Despite the sharp rise in...

09/05/2008

Vascular Disease Management

Case Report

Use of Bivalirudin for Suspected Heparin-Induced Thrombocytopenia during Lower Extremity Revascularization

09/05/2008

Advantages of various direct thrombin inhibitors, a modified dosing schedule for bivalrudin, and experience with monitoring parameters are described. These advantages may form the basis for consideration when alternative anticoagulation to...

Advantages of various direct...

09/05/2008

Vascular Disease Management

Review

Current Clinical Applications of Bivalirudin: An Overview

09/05/2008

Bivalirudin is a direct thrombin inhibitor with specific and reversible actions.It is a synthetic, 20-amino acid peptide with a molecular weight of 2180 daltons. Bivalirudin directly inhibits both circulating and bound thrombin by binding to...

Bivalirudin is a direct thrombin...

09/05/2008

Vascular Disease Management